The chances of a non-liposomal active substance reaching the tissues through oral administration are around 10%. Therefore, the only way to benefit significantly from a non-liposomal active substance is through injection. Injection is a traumatic method that is not preferred by many users, and it also requires time and cost as it can only be done in healthcare facilities. Another future-oriented reason for choosing liposome technology is the potential for saving on the bioactive substance used in liposomes.
